[go: up one dir, main page]

WO2007057768A2 - Derives de sulfonyle - Google Patents

Derives de sulfonyle Download PDF

Info

Publication number
WO2007057768A2
WO2007057768A2 PCT/IB2006/003287 IB2006003287W WO2007057768A2 WO 2007057768 A2 WO2007057768 A2 WO 2007057768A2 IB 2006003287 W IB2006003287 W IB 2006003287W WO 2007057768 A2 WO2007057768 A2 WO 2007057768A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aryl
cycloalkyl
membered heterocycle
term
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/003287
Other languages
English (en)
Other versions
WO2007057768A3 (fr
Inventor
Hengmiao Cheng
Stephan James Cripps
Jennifer Anne Lafontaine
Phuong Thi Quy Le
Jean Joo Matthews
Sajiv Krishnan Nair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of WO2007057768A2 publication Critical patent/WO2007057768A2/fr
Publication of WO2007057768A3 publication Critical patent/WO2007057768A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Definitions

  • the present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme (11- ⁇ -hsd-1).
  • Metabolic Syndrome e.g. raised blood pressure, decreased levels of HDL and increased levels of VLDL
  • VLDL VLDL
  • Obesity is an important factor in Metabolic Syndrome as well as in the majority (>80%) of type 2 diabetic, and omental fat appears to be of central importance.
  • Inhibition of the enzyme in pre-adipocytes (stromal cells) has been shown to decrease the rate of differentiation into adipocytes. This is predicted to result in diminished expansion (possibly reduction) of the omental fat depot, i.e.
  • 11- ⁇ -hsd-1 is suggested to have a role in aqueous production, rather than drainage, but it is presently unknown if this is by interfering with activation of the glucocorticoid or the mineralocorticoid receptor, or both.
  • the invention relates to a compound of the formula (I):
  • n is 0 or 1 ;
  • R 1 is H, halo, CN, C r C 6 a!ky!, OR 7 , C r C 6 alkyl-OR 7 , NR 7 R 8 , C r C 6 alkyl-NR 7 R 8 , aryl, heterocycle, (C 1 -
  • R 2 and R 3 are each independently H, Ci-C 5 alkyl, (CR 7 R 8 ) m OR 9 wherein m is an integer from 0 -4, aryl, (C 1 -
  • C 4 alkyl)aryl or may together optionally cyclize to form a non-aromatic 4-6 membered heterocycle which is optionally further substituted with a C r C B alkyl;
  • R 4 is d-Cealkyl, CrC 6 alkyl-OR 7 , cycloalkyl, aryl, (4 to 10)-membered heterocycle, (C r C 4 alkyl)-cycloalkyl,
  • R 4 is optionally substituted with 1-4 R 6 groups
  • R 5 is H, C r C 6 alkyl, or cycloalkyl
  • R 6 is independently selected from the group consisting of halo, CN, CF 3 , CHF 2 , CH 2 F, trifluoromethoxy, OR 7 , CrCealkyl, d-Cealkenyl, C r C 6 alkynyl, (CR 7 R 8 ) P CONR S R 10 , (CR 7 R 8 ) P NRC(O)R 9 , (CR 7 R 8 ) P NR 9 R 10 ,
  • R 7 , R 8 , R 9 , R 10 and R 11 are each independently selected from the group of H, d-Cealkyl, cycloalkyl, aryl,
  • R 6 substituents can optionally be further substituted with 1-4 R 12 .
  • R 12 is independently selected from the group consisting of halo, CN, CF 3 , CHF 2 , CH 2 F, trifluoromethoxy,
  • R 13 , R 14 , R 15 , R 15 and R 17 are each independently selected from the group of H, C r C e alkyl, cycloalkyl, aryl, (4 to 10)-membered heterocycle, (Ci-C 4 alky))-cycloalkyl, (C 1 -C 4 alkyl)aryl, and (C- ⁇ -C 4 alkyl)- (4 to 10)-membered heterocycle.
  • n 0.
  • the invention relates to a compound of the formula (II):
  • R 1 is H, halo, CN, C r C 6 alkyl, OR 7 , C r C 6 alkyl-OR 7 , NR 7 R 8 , C r C 6 alkyl-NR 7 R 8 , aryl, heterocycle, (C 1 -
  • R 2 and R 3 together cyclize to form a non-aromatic 4-6 membered heterocycle which is optionally further substituted with a C r C 6 alkyl;
  • R 4 is C r C 6 alkyl, C r C 6 alkyl-OR 7 , cycloalkyl, aryl, (4 to 10)-membered heterocycle, (C r C 4 alkyl)-cycloalkyl,
  • R 4 is optionally substituted with 1-4 R 6 groups
  • R 5 is H, C r C 6 alkyl, or cycloalkyl
  • R 6 is independently selected from the group consisting of halo, CN, CF 3 , CHF 2 , CH 2 F, trifluoromethoxy, OR 7 , C r C 6 alkyl, C r C 6 alkenyl, d-C 6 alkynyl, (CR r R 8 ) p CONR 9 R 10 , (CR 7 R 8 ) P NRC(O)R 9 , (CR 7 R 8 ) P NR 9 R 1Q ,
  • R 7 , R 8 , R 9 , R 10 and R 11 are each independently selected from the group of H, C r C 6 alkyl, cycloalkyl, aryl,
  • R 6 substituents can optionally be further substituted with 1-4 R 12 .
  • R 12 is independently selected from the group consisting of halo, CN, CF 3 , CHF 2 , CH 2 F, trifluoromethoxy, OR 13 , d-C ⁇ alkyl, C r C 6 alkenyl, C r C 6 alkynyl, (CR 13 R 14 ) q CONR 15 R 16 , (CR 13 R 14 ) q NRC(O)R 1s , (CR 13 R 14 ) q NR 15 R 18 , (CR 13 R 14 ) q COR 15 , (CR 13 R 14 ) q CO 2 R 15 , cycloalkyl, aryl, (4 to 10)-membered heterocycle, (C r C 4 all ⁇ yl)-cycloalkyl, (CrC 4 alkyl)aryl, (C r C 4 alkyl)- (4 to 10)-membered heterocycle, (CR 13 R 14 ) q SO 2 R 15 , (CR 13 R 14 ) q SOR 1
  • R 13 , R 14 , R 15 , R 16 and R 17 are each independently selected from the group of H, C-pCgalkyl, cycloalkyl, aryl, (4 to 10)-membered heterocycle, (Ci-C 4 alkyl)-cycloalkyl, (Ci-C 4 alkyl)aryl, and (CrC 4 alkyl)- (4 to 10)-membered heterocycle.
  • n is 0 and R 2 and R 3 together cyclize to form a morpholine.
  • n is 0 and R 2 and R 3 together cyclize to form a pyrrolidine.
  • n is 0 and R 2 and R 3 together cyclize to form an azabicyclo[3.1.0]hexane.
  • n 1
  • n is 1 and R 2 and R 3 together cyclize to form a piperidine.
  • the invention relates to pharmaceutical compositions having an effective amount of any of these compounds or pharmaceutically acceptable salts or solvates thereof, and a pharmaceutically acceptable carrier.
  • the invention relates to methods for treating conditions that are mediated by the modulation of the 11- ⁇ -hsd-1 enzyme by administering to a mammal an effective amount of any of these compounds or pharmaceutically acceptable salts or solvates thereof.
  • the invention relates to methods for treating diabetes, metabolic syndrome, insulin resistance syndrome, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, osteoporosis, tuberculosis, atherosclerosis, dementia, depression, viral diseases, ophthalmic disorders, inflammatory disorders, or diseases in which the liver is a target organ by administering to a mammal an effective amount of any of these compounds or pharmaceutically acceptable salts or solvates thereof.
  • the invention relates to methods for treating glaucoma by administering to a mammal an effective amount of any of these compounds or pharmaceutically acceptable salts or solvates thereof.
  • the invention relates to methods for treating glaucoma by administering to a mammal an effective amount of any of these compounds or pharmaceutically acceptable salts or solvates thereof, in combination with latanoprost.
  • the invention relates to methods for treating glaucoma by administering to a mammal an effective amount of any of these compounds or pharmaceutically acceptable salts or solvates thereof, in combination with a carbonic anhydrase inhibitor.
  • the invention relates to methods for treating glaucoma by administering to a mammal an effective amount of any of these compounds or pharmaceutically acceptable salts or solvates thereof, in combination with an EP2 or EP4 agonist.
  • the invention relates to methods for treating diabetes by administering to a mammal an effective amount of any of these compounds or pharmaceutically acceptable salts or solvates thereof, in combination with a PPAR agonist.
  • alkyl as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight or branched moieties.
  • alkyl groups of the invention include Ci-C 6 alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl and so on.
  • alkenyl as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon double bond wherein alkyl is as defined above and including E and Z isomers of said alkenyl moiety.
  • alkynyl as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon triple bond wherein alkyl is as defined above.
  • alkoxy as used herein, unless otherwise indicated, includes O-alkyl groups wherein alkyl is as defined above.
  • amino as used herein, is intended to include the -NH 2 radical, and any substitutions of the N atom.
  • heteroalkyl alkyl, alkenyl and alkynyl radicals and which have one or more skeletal chain atoms selected from an atom other than carbon (oxygen, nitrogen, sulfur, phosphorus or combinations thereof).
  • heteroalkyls, heteroalkenyls and heteroalkynyls include, e.g.
  • trifluoromethyl is meant to represent a -CF 3 group.
  • trifluoromethoxy is meant to represent a -OCF 3 group.
  • cyano as used herein, is meant to represent a -CN group.
  • OMs as used herein, is intended to mean, unless otherwise indicated is intended to mean methanesulfonate.
  • HOBt 1 -hydroxybenzotriazole is intended to mean, unless otherwise indicated is intended to mean 1 -hdroxybenzotriazole.
  • Me as used herein, unless otherwise indicated, is intended to mean means methyl.
  • MeOH as used herein, unless otherwise indicated, is intended to mean means methanol.
  • Et 2 O as used herein, unless otherwise indicated, is intended to mean means diethylether.
  • EtOH as used herein, unless otherwise indicated, is intended to mean means ethanol.
  • Et 3 N as used herein, unless otherwise indicated, is intended to mean means triethylamine.
  • EtOAc is ethyl acetate
  • TFA trifluoroacetic acid
  • TEA triethanolamine
  • HATU N,N,N',N'- tetramethyluronium hexafluorophosphate.
  • DIPEA diisopropyl ethyl amine
  • DCE diisopropyl ethyl amine
  • THF tetrahydrofuran
  • BHT butylated hydroxy toluene
  • Boc t-butoxycarbonyl
  • (Boc) 2 O is intended to mean di-tert-butyl dicarbonate.
  • CBZ 1 as used herein, unless otherwise indicated is intended to mean benzyloxycarbonyl.
  • NMM N-methyl- morpholine
  • MTBE tert-butyl methyl ether
  • DMAP 4- (dimethylamino)pyridine
  • EDC 1-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.
  • TIOH thallium(l) hydroxide
  • TIOEt as used herein, unless otherwise indicated, is intended to mean thallium(l) ethoxide.
  • PCy 3 as used herein, is intended to mean tricyclohexylphosphine.
  • Pd 2 (dba) 3 is intended to mean tris(dibenzylideneacetone)dipalladium(0).
  • Pd(OAc) 2 is intended to mean palladium(ll) acetate.
  • Pd(PPh 3 ) 2 Cl 2 is intended to mean dichlorobis(triphenylphosphine)palladium(ll).
  • Pd(PPh 3 ) 4 as used herein, unless otherwise indicated, is intended to mean tetrakis(triphenylphophine)palladium(0).
  • Pd(dppf)CI 2 is intended to mean (1 ,1'-bis(diphenylphosphino)ferrocene)dichloropalladium(ll), complex with dichloromethane (1:1 ).
  • Pd/C palladium on carbon
  • PyBOP as used herein, unless otherwise indicated, is intended to mean benzotriazol- 1 -yl-oxytripyrrolidinophosphonium hexafluorophosphate.
  • DIEA as used herein unless otherwise indicated, is intended to mean N 1 N- diisopropylethylamine.
  • G6P glucose-6- phosphate
  • NIDDM non insulin dependent diabetes mellitus
  • NAHMDS sodium bis(trimethylsilyl)amide.
  • NADPH nicotinamide adenine dinucleotide phosphate, reduced form.
  • CD 3 OD is intended to mean deuteromethanol.
  • CD 3 CN is intended to mean deuteroacetonitrile.
  • DEAD is intended to mean diethyl azodicarboxylate.
  • DIAD diisopropyl azodicarboxylate
  • TsCH 2 NC is intended to mean tosylmethyl isocyanide.
  • CISO 3 H is intended to mean chlorosulfonic acid.
  • DMSO-d s or "DMSO-D 6 ,” as used herein, is intended to mean deuterodimethyl sulfoxide.
  • DME is intended to mean 1 ,2-dimethoxyethane.
  • DMF is intended to mean ⁇ /, ⁇ /-dimethylformamide.
  • DMSO dimethylsulfoxide
  • Dl deionized
  • KAc potassium acetate
  • mmol as used herein, is intended to mean millimole.
  • mm as used herein, is intended to mean millimeter.
  • min is intended to mean minute.
  • ⁇ l_ is intended to mean microliter.
  • ⁇ M is intended to mean micromolar.
  • ⁇ m is intended to mean micrometer.
  • M is intended to mean molar.
  • N is intended to mean normal.
  • nanometer is intended to mean nanometer.
  • nM is intended to mean nanoMolar.
  • wt/wt is intended to mean weight/weight.
  • v/v is intended to mean volume/volume.
  • UV ultraviolet
  • APCI-MS atmospheric pressure chemical ionization mass spectroscopy
  • HPLC high performance liquid chromatograph
  • LC liquid chromatograph
  • LCMS liquid chromatography mass spectroscopy
  • ELSD evaporative light scattering detection
  • MS mass spectroscopy
  • HRMS electrospray ionization
  • NA as used herein, unless otherwise indicated, is intended to mean not available.
  • RT room temperature
  • Celite ® as used herein, unless otherwise indicated, is intended to mean a white solid diatomite filter agent commercially available from World Minerals located in Los Angeles, California USA.
  • Ki is intended to mean values of enzyme inhibition constant.
  • Kj is intended to mean K, apparent.
  • IC 50 is intended to mean concentrations required for at least 50% enzyme inhibition.
  • cycloalkyl refers to a non-aromatic, saturated or partially saturated, monocyclic or fused, spiro or unfused bicyclic or tricyclic hydrocarbon referred to herein containing a total of from 3 to 9 carbon atoms, preferably 5-8 ring carbon atoms.
  • exemplary cycloalkyls include monocyclic rings having from 3-9 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and adamantyl.
  • Illustrative examples of cycloalkyl are derived from, but not limited to, the following:
  • aryl as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl.
  • (4 to 10)-membered heterocyclyl includes aromatic and non-aromatic heterocyclic groups containing one to four heteroatoms each selected from O, S and N, wherein each heterocyclic group has from 4-10 atoms, respectively, in its ring system, and with the proviso that the ring of said group does not contain two adjacent O or S atoms.
  • Non-aromatic heterocyclic groups include groups having only 3 atoms in their ring system, but aromatic heterocyclic groups must have at least 5 atoms in their ring system.
  • the heterocyclic groups include benzo-fused ring systems.
  • An example of a 3 membered heterocyclic group is aziridine, an example of a 4 membered heterocyclic group is azetidinyl (derived from azetidine).
  • An example of a 5 membered heterocyclic group is thiazolyl, an example of a 7 membered ring is azepinyl, and an example of a 10 membered heterocyclic group is qui ⁇ olinyl.
  • non-aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1 ,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3- pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1 ,3-dioxolanyl, pyrazolin
  • aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, fury], thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinox
  • a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached).
  • a group derived from imidazole may be imidazol-1-yl (N-attached) or imidazol-2-yl (C-attached).
  • the 4 to 10 membered heterocyclic may be optionally substituted on any ring carbon, sulfur, or nitrogen atom(s) by one to two oxo, per ring.
  • heterocyclic group wherein the ring atoms are substituted with oxo moieties is 1,1-dioxo-thiomorpholinyl.
  • a “solvate” is intended to mean a pharmaceutically acceptable solvate form of a specified compound that retains the biological effectiveness of such compound.
  • solvates include compounds of the invention in combination with water, isopropanol, ethanol, methanol, DMSO (dimethylsulfoxide), ethyl acetate, acetic acid, or ethanolamine.
  • the compounds of the present invention may have asymmetric carbon atoms. The carbon- carbon bonds of the compounds of the present invention may be depicted herein using a solid line
  • a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers are meant to be included.
  • the use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of the invention and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is present.
  • Solutions of individual stereoisomeric compounds of the present invention may rotate plane- polarized light.
  • the use of either a "(+)" or “(-)” symbol in the name of a compound of the invention indicates that a solution of a particular stereoisomer rotates plane-polarized light in the (+) or (-) direction, as measured using techniques known to those of ordinary skill in the art.
  • Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixtures into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. All such isomers, including diastereomeric mixtures and pure enantiomers are considered as part of the invention.
  • individual stereoisomeric compounds of the present invention may be prepared in enantiomerically enriched form by asymmetric synthesis.
  • Asymmetric synthesis may be performed using techniques known to those of skill in the art, such as the use of asymmetric starting materials that are commercially available or readily prepared using methods known to those of ordinary skill in the art, the use of asymmetric auxiliaries that may be removed at the completion of the synthesis, or the resolution of intermediate compounds using enzymatic methods.
  • the choice of such a method will depend on factors that include, but are not limited to, the availability of starting materials, the relative efficiency of a method, and whether such methods are useful for the compounds of the invention containing particular functional groups. Such choices are within the knowledge of one of ordinary skill in the art.
  • the derivative salts, prodrugs and solvates may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and/or diastereomers. All such single stereoisomers, racemates, and mixtures thereof are intended to be within the scope of the present invention.
  • an optically pure compound is one that is enantiomerically pure.
  • the term "optically pure” is intended to mean a compound comprising at least a sufficient activity.
  • an optically pure amount of a single enantiomer to yield a compound having the desired pharmacological pure compound of the invention comprises at least 90% of a single isomer (80% enantiomeric excess), more preferably at least 95% (90% e.e.), even more preferably at least 97.5% (95% e.e.), and most preferably at least 99% (98% e.e.).
  • a desired salt may be prepared by any suitable method known to the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid; hydrobromic acid; sulfuric acid; nitric acid; phosphoric acid; and the like, or with an organic acid, such as acetic acid; maieic acid; succinic acid; mandelic acid; fumaric acid; malonic acid; pyruvic acid; oxalic acid; glycolic acid; salicylic acid; pyranosidyl acid, such as glucuronic acid or galacturonic acid; alpha-hydroxy acid, such as citric acid or tartaric acid; amino acid, such as aspartic acid or glutamic acid; aromatic acid, such as benzoic acid or cinnamic acid; sulfonic acid, such as p- toluenesulfonic acid or ethanesulfonic acid; and the like.
  • an inorganic acid such as hydrochloric acid; hydrobromic acid; sulfuric acid
  • a desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary); an alkali metal or alkaline earth metal hydroxide; or the like.
  • suitable salts include organic salts derived from amino acids such as glycine and arginine; ammonia; primary, secondary, and tertiary amines; and cyclic amines, such as piperidine, morpholine, and piperazine; as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
  • derivatives, prodrugs, salts, or solvates that are solids
  • the derivatives, prodrugs, salts, and solvates used in the method of the invention may exist in different polymorph or crystal forms, all of which are intended to be within the scope of the present invention and specified formulas.
  • the derivative, salts, prodrugs and solvates used in the method of the invention may exist as tautomers, all of which are intended to be within the broad scope of the present invention.
  • the compounds of the present invention that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the compound of the present invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt.
  • the acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained.
  • the desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding to the solution an appropriate mineral or organic acid.
  • Those compounds of the present invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
  • such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques.
  • the chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of the present invention.
  • Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium calcium and magnesium, etc.
  • salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure.
  • they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before.
  • stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product.
  • Certain compounds may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers and stereoisomers of the compounds and mixtures thereof, are considered to be within the scope of the invention.
  • the invention includes the use of a racemate, one or more enantiomeric forms, one or more diastereomeric forms, or mixtures thereof.
  • the compounds may also exist as tautomers. This invention relates to the use of all such tautomers and mixtures thereof.
  • Certain functional groups contained within the compounds of the present invention can be substituted for bioisosteric groups, that is, groups which have similar spatial or electronic requirements to the parent group, but exhibit differing or improved physicochemical or other properties. Suitable examples are well known to those of skill in the art, and include, but are not limited to moieties described in Patini et al., Chem. Rev, 1996, 96, 3147-3176 and references cited therein.
  • the subject invention also includes isotopically-labelled compounds, which are identical to those described but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 0, 17 0, 31 P, 32 P, 35 S, 18 F, and 36 CI, respectively.
  • Compounds of the present invention and pharmaceutically acceptable salts or solvates of said compounds which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention.
  • Certain isotopically-labelled compounds of the present invention for example those into which radioactive isotopes such as 3 H and 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability.
  • lsotopically labeled compounds of the invention can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
  • phrases "pharmaceutically acceptable salt(s)", as used herein, unless otherwise indicated, includes salts of acidic or basic groups which may be present in the compounds of the invention. Such compounds that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
  • the acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, Le., salts containing pharmacologically acceptable anions, such as the acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edislyate, estolate, esylate, ethylsuccinate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylsulfate, mucate,
  • Methodabolic syndrome means psoriasis, diabetes mellitus, wound healing, inflammation, neurodegenerative diseases, galactosemia, maple syrup urine disease, phenylketonuria, hypersarcosinemia, thymine uraciluria, sulfinuria, isovaleric acidemia, saccharopinuria, 4-hydroxybutyric aciduria, glucose-6-phosphate dehydrogenase deficiency, and pyruvate dehydrogenase deficiency.
  • treating means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
  • treatment refers to the act of treating as “treating” is defined immediately above.
  • modulate refers to the ability of a modulator for a member of the steroid/thyroid superfamily to either directly (by binding to the receptor as a ligand) or indirectly (as a precursor for a ligand or an inducer which promotes production of ligand from a precursor) induce expression of gene(s) maintained under hormone expression control, or to repress expression of gene(s) maintained under such control.
  • “obese” is defined, for males, as individuals whose body mass index is greater than 27.8 kg/m 2 , and for females, as individuals whose body mass index is greater than 27.3 kg/m 2 .
  • the invention method is not limited to those who fall within the above criteria. Indeed, the method of the invention can also be advantageously practiced by individuals who fall outside of these traditional criteria, for example, by those who may be prone to obesity.
  • inflammatory disorders refers to disorders such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, chondrocalcinosis, gout, inflammatory bowel disease, ulcerative colitis, Crohn's disease, fibromyalgia, and cachexia.
  • terapéuticaally effective amount refers to that amount of drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal, or human that is being sought by a researcher, veterinarian, medical doctor or other.
  • amount . . . effective to lower blood glucose levels refers to levels of compound sufficient to provide circulating concentrations high enough to accomplish the desired effect.
  • Such a concentration typically falls in the range of about 10 nM up to 2 ⁇ M; with concentrations in the range of about 100 nM up to 500 nM being one example.
  • concentrations typically falls in the range of about 10 nM up to 2 ⁇ M; with concentrations in the range of about 100 nM up to 500 nM being one example.
  • insulin resistance refers to the reduced sensitivity to the actions of insulin in the whole body or individual tissues, such as skeletal muscle tissue, myocardial tissue, fat tissue or liver tissue. Insulin resistance occurs in many individuals with or without diabetes mellitus.
  • insulin resistance syndrome refers to the cluster of manifestations that include insulin resistance, hyperinsulinemia, non insulin dependent diabetes mellitus (NIDDM), arterial hypertension, central (visceral) obesity, and dyslipidemia.
  • NIDDM non insulin dependent diabetes mellitus
  • bioisosteric groups that is, groups which have similar spatial or electronic requirements to the parent group, but exhibit differing or improved physicochemical or other properties.
  • Suitable examples are well known to those of skill in the art, and include, but are not limited to moieties described in Patini et al.,
  • the compounds of the present invention are modulators of 11- ⁇ -hsd-1.
  • the compounds of the present invention may modulate processes mediated by 11- ⁇ -hsd-1 , which refer to biological, physiological, endocrinological, and other bodily processes which are mediated by receptor or receptor combinations which are responsive to the 11- ⁇ -hsd-1 inhibitors described herein (e.g., diabetes, hyperlipidemia, obesity, impaired glucose tolerance, hypertension, fatty liver, diabetic complications (e.g. retinopathy, nephropathy, neurosis, cataracts and coronary artery diseases and the like), arteriosclerosis, pregnancy diabetes, polycystic ovary syndrome, cardiovascular diseases (e.g.
  • ischemic heart disease and the like cell injury (e.g.) brain injury induced by strokes and the like) induced by atherosclerosis or ischemic heart disease, gout, inflammatory diseases (e.g. arthrosteitis, pain, pyrexia, rheumatoid arthritis, inflammatory enteritis, acne, sunburn, psoriasis, eczema, allergosis, asthma, Gl ulcer, cachexia, autoimmune diseases, pancreatitis and the like), cancer, osteoporosis and cataracts. Modulation of such processes can be accomplished in vitro or in vivo. In vivo modulation can be carried out in a wide range of subjects, such as, for example, humans, rodents, sheep, pigs, cows, and the like.
  • inflammatory diseases e.g. arthrosteitis, pain, pyrexia, rheumatoid arthritis, inflammatory enteritis, acne, sunburn, psoriasis, e
  • the compounds according to the present invention may be used in several indications which involve modulations of 11- ⁇ -hsd-1 enzyme.
  • the compounds according to the present invention may be used against dementia (see WO97/07789), osteoporosis (see Canalis E 1996, Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis, Journal of Clinical Endocrinology and Metabolism, 81 , 3441-3447) and may also be used disorders in the immune system (see Franchimont et al, "Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat 4 phosphorylation in T lymphocytes", The Journal of Immunology 2000, Feb 15, vol 164 (4), pages 1768-74) and also in the above listed indications.
  • Adrenalectomy attenuates the effect of fasting to increase both food intake and hypothalamic neuropeptide Y expression. This supports the role of glucocorticoids in promoting food intake and suggests that inhibition of 11- ⁇ -hsd-1 in the brain might increase satiety and therefore reduce food intake (Woods, S.C., et al., (1998), Science, 280:1378-1383).
  • Glucocorticoids were previously known to reduce pancreatic insulin release in vivo (Billaudel, B. and
  • glucocorticoids suppress the immune system. But in fact there is a dynamic interaction between the immune system and the HPA (hypothalamo-pituitary-adrenal) axis (Rook, G. A.W., (1999), Baillier's Clin. Endocrinol Metab., 13: 576-581).
  • HPA hypothalamo-pituitary-adrenal
  • the balance between the cell- mediated response and humoral responses is modulated by glucocorticoids.
  • a high glucocorticoid activity such as at a state of stress, is associated with a humoral response.
  • inhibition of the enzyme 11- ⁇ - hsd-1 has been suggested as a means of shifting the response towards a cell-based reaction.
  • 11- ⁇ -hsd-1 In the eye, expression of 11- ⁇ -hsd-1 is confined to basal cells of the corneal epithelium and the non-pigmented epithelialium of the cornea (the site of aqueous production), to ciliary muscle and to the sphincter and dilator muscles of the iris.
  • the distant isoenzyme 11 beta-hydroxysteroid dehydrogenase type 2 is highly expressed in the non-pigmented ciliary epithelium and corneal endothelium. None of the enzymes is found at the trabecular meshwork, the site of drainage.
  • 11- ⁇ -hsd-1 is suggested to have a role in aqueous production, rather than drainage, but it is presently unknown if this is by interfering with activation of the glucocorticoid or the mineralocorticoid receptor, or both.
  • Glucocorticoids have an essential role in skeletal development and function but are detrimental in excess.
  • Glucocorticoid-induced bone loss is derived, at least in part, via inhibition of bone formation, which includes suppression of osteoblast proliferation and collagen synthesis (Kim, CH. , Cheng, S.L, and Kim, G.S., (1999) J. Endocrinol., 162: 371-379).
  • the negative effect on bone nodule formation could be blocked by the non-specific inhibitor carbenoxolone suggesting an important role of 11- ⁇ -hsd-1 in the glucocorticoid effect (Bellows, CG. , Ciaccia, A. and.
  • the compounds of the present invention may also be useful in the treatment of other metabolic disorders associated with impaired glucose utilization and insulin resistance include major late-stage complications of NIDDM, such as diabetic angiopathy, atherosclerosis, diabetic nephropathy, diabetic neuropathy, and diabetic ocular complications such as retinopathy, cataract formation and glaucoma, and many other conditions linked to NIDDM, including dyslipidemia glucocorticoid induced insulin resistance, dyslipidemia, polycysitic ovarian syndrome, obesity, hyperglycemia, hyperlipidemia, hypercholesteremia, hypertriglyceridemia, hyperinsulinemia, and hypertension. Brief definitions of these conditions are available in any medical dictionary, for instance, Stedman's Medical Dictionary (10 th Ed.). Assay
  • the inhibition constant, Ki was measured in a buffer containing 100 mM triethanolamine, 200 mM NaCI, 0.02% n-dodecyl ⁇ -maltoside, 5% glycerol, 5 mM ⁇ -mercaptoethanol, 1% DMSO, pH 8.0.
  • the activity of human 11b-hsd-1 is measured on a Corning 96-well plate for a total volume of 300 uL/well in the presence and absence of inhibitor. In each well, varying amounts of compounds are incubated with a fixed amount of 11b-hsd-1 (4 nM) and NADPH (500 uM) for 30 to 40 min at room temperature in the assay buffer.
  • the enzyme concentration was determined by titration using reversible tight-binding inhibitors.
  • the activity remaining after the pre-incubation period is measured by adding a fixed concentration of 3H-cortisone (200 nM) and the regeneration system constituted with 2 mM glucose- 6-phosphate, 1 U/mL glucose-6-phosphate dehydrogenase and 6 mM MgCI 2 .
  • the final concentration of cortisone in the assay buffer is lower than the K m value (328 nM).
  • the enzyme activity is quenched by mixing an aliquot of the assay buffer with an equal volume of DMSO in a second 96-well plate.
  • Vj, and V 0 are the rates of Cortisol formation in the presence and in the absence of inhibitor, respectively, I is the inhibitor concentration and E is the 11b-hsd-1 concentration in the assay buffer. All the concentrations reported are the final concentrations in the assay buffer
  • Glucose-6-Phosphate dehydrogenase was purchased from Sigma.
  • HEK293-11 ⁇ HSD1/GRE-Luciferase cell-based assay ECm determination Inhibition of 11 ⁇ HSD1 enzyme activity was measured using human kidney HEK293 stable transfected cells, over-expressing human 11 ⁇ HSD1 , and a reporter plasmid containing DNA sequences for specific recognition of glucocorticoid-activated glucocorticoid receptors (GRE), using a method similar to that described in Bujalska et al, Human 11 ⁇ -hydroxysteroid dehydrogenase: Studies on the stably transfected isoforms nd localization of the type 2 isozyme within renal tissue, Steroids, 62(1), 1991 , pp 77- 82 .
  • 11 ⁇ HSD1 is responsible for converting inactive into active glucocorticoids (cortisone to Cortisol, in humans).
  • Cortisol but not cortisone
  • GR glucocorticoid receptors
  • a compound with the capability of inhibiting 11 ⁇ HSD1 will reduce the luciferase signal, compare to cortisone control (enzyme substrate).
  • the compounds of the invention may be provided in suitable topical, oral and parenteral pharmaceutical formulations for use in the treatment of 11- ⁇ -hsd-1 mediated diseases.
  • the compounds of the present invention may be administered orally as tablets or capsules, as oily or aqueous suspensions, lozenges, troches, powders, granules, emulsions, syrups or elixirs.
  • the compositions for oral use may include one or more agents for flavoring, sweetening, coloring and preserving in order to produce pharmaceutically elegant and palatable preparations. Tablets may contain pharmaceutically acceptable excipients as an aid in the manufacture of such tablets.
  • these tablets may be coated with a pharmaceutically acceptable enteric coating, such as glyceryl monostearate or glyceryl distearate, to delay disintegration and absorption in the gastrointestinal tract to provide a sustained action over a longer period.
  • a pharmaceutically acceptable enteric coating such as glyceryl monostearate or glyceryl distearate
  • Formulations for oral use may be in the form of hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin.
  • the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
  • Aqueous suspensions normally contain active ingredients in admixture with excipients suitable for the manufacture of an aqueous suspension.
  • excipients may be a suspending agent, such as sodium carboxymethyl cellulose, methyl cellulose, hydroxypropylmethyl cellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; a dispersing or wetting agent that may be a naturally occurring phosphatide such as lecithin, a condensation product of ethylene oxide and a long chain fatty acid, for example polyoxyethylene stearate, a condensation product of ethylene oxide and a long chain aliphatic alcohol such as heptadecaethylenoxycetanol, a condensation product of ethylene oxide and a partial ester derived from a fatty acid and hexitol such as polyoxyethylene sorbitol monooleate or a fatty acid hexitol anhydrides such as polyoxyethylene sorbitan mono
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension, This suspension may be formulated according to known methods using those suitable dispersing or wetting agents and suspending agents that have been mentioned above.
  • the sterile injectable preparation may also be formulated as a suspension in a non toxic perenterally-acceptable diluent or solvent, for example as a solution in 1 ,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringers solution and isotonic sodium chloride solution.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • the compounds may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at about 25 Celcius but liquid at rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non-irritating excipient that is solid at about 25 Celcius but liquid at rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials include cocoa butter and other glycerides.
  • topical use preparations for example, creams, ointments, jellies solutions, or suspensions, containing the compounds of the present invention are employed.
  • the compounds may also be administered in the form of liposome delivery systems such as small unilamellar vesicles, large unilamellar vesicles and multimellar vesicles.
  • Liposomes can be formed from a variety of phospholipides, such as cholesterol, stearylamine or phosphatidylcholines.
  • Dosage levels of the compounds of the present invention are of the order of about 0.5 mg/kg body weight to about 100 mg/kg body weight.
  • An exemplary dosage rate is between about 30 mg/kg body weight to about 100 mg/kg body weight. It will be understood, however, that the specific dose level for any particular patient will depend upon a number of factors including the activity of the particular compound being administered, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
  • a compound of the present invention is delivered in a pharmaceutically acceptable ophthalmic vehicle such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the cornea and/or sclera and internal regions of the eye, including, for example, the anterior chamber, posterior chamber, vitreous body, aqueous humor, vitreous humor, cornea, iris/ciliary's, lens, choroid/retina and sclera.
  • the pharmaceutically acceptable ophthalmic vehicle may be an ointment, vegetable oil, or an encapsulating material.
  • a compound of the invention may also be injected directly into the vitreous humor or aqueous humor.
  • a compound may be also be administered by well known, acceptable methods, such as subtenon and/or subconjunctival injections.
  • the macula is comprised primarily of retinal cones and is the region of maximum visual acuity in the retina.
  • a Tenon's capsule or Tenon's membrane is disposed on the sclera.
  • a conjunctiva covers a short area of the globe of the eye posterior to the limbus (the bulbar conjunctiva) and folds up (the upper cul-de-sac) or down (the lower cul-de-sac) to cover the inner areas of the upper eyelid and lower eyelid, respectively.
  • the conjunctiva is disposed on top of Tenon's capsule.
  • the sclera and Tenon's capsule define the exterior surface of the globe of the eye.
  • age related macular degeneration choroid neovascularization, retinopathies (such as diabetic retinopathy, retinopathy of prematurity), retinitis, uveitis, cystoid macular edema (CME), glaucoma, and other diseases or conditions of the posterior segment of the eye
  • ARMD and CME it is most preferable to dispose the depot directly on the outer surface of the sclera, below Tenon's capsule, and generally above the macula.
  • the compounds may be formulated as a depot preparation. Such long-acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) intramuscular injection or by the above mentioned subtenon or intravitreal injection.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • the compounds may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form.
  • the solution or suspension may be prepared in its pure form and administered several times daily.
  • the present compositions, prepared as described above may also be administered directly to the cornea.
  • the composition is prepared with a muco-adhesive polymer which binds to cornea.
  • the compounds may be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion-exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • a pharmaceutical carrier for hydrophobic compounds is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase.
  • the cosolvent system may be a VPD co-solvent system.
  • VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol.
  • the VPD co-solvent system (VPD:5W) contains VPD diluted 1:1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration.
  • co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics.
  • identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g. polyvinyl pyrrolidone; and other sugars or polysaccharides may be substituted for dextrose.
  • hydrophobic pharmaceutical compounds may be employed.
  • Liposomes and emulsions are known examples of delivery vehicles or carriers for hydrophobic drugs.
  • Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity.
  • the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent.
  • sustained-release materials have been established and are known by those skilled in the art. Sustained- release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.
  • compositions also may comprise suitable solid- or gel-phase carriers or excipients.
  • suitable solid- or gel-phase carriers or excipients include calcium carbonate, calcium phosphate, sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
  • Some of the compounds of the invention may be provided as salts with pharmaceutically compatible counter ions.
  • Pharmaceutically compatible salts may be formed with many acids, including hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free-base forms.
  • the compounds of the invention may be prepared according to U.S. Provisional Patent Application No. 60/569,362, the entirety of which is hereby incorporated by reference.
  • NMR data was acquired on a Bruker DRX 300 NMR Spectrometer ® using a broadband decoupling scheme to decouple the protons from the carbons.
  • the Bruker DRX 300 NMR Spectrometer ® is commercially available from Buker Biospin Corporation of Billercia, Massachusetts.
  • Purification Conditions included a Waters ® Bondapak column C18, 37-55 micron (particle size), 47x300 mm (column size) having a flow rate of 75 mL/min, a detector of UV 220 nm, where Buffer A is: 0.1 %HOAc in H 2 O and Buffer B is: 0.1%HOAc in CH 3 CN.
  • the Waters ® Bondapak column C18 is commercially available from Varian, Inc. of Palo Alto, California, USA.
  • the column was equilibrated in Buffer A for 20 min.
  • the sample was dissolved in 10 mL of DMSO, filtered, and injected onto the column.
  • the gradient was held at 100% in Buffer A for 5 min and then increased linearly to 90%Buffer A/10%Buffer B in 20 min and then held at 10% Buffer B for another 25 min.
  • the desired product came out at about 26 min during the isocratic hold of the gradient.
  • the fractions were checked, pooled, and lyophilized to afford a syrup.
  • Analytical LCMS Method Post-purification
  • the compound of formula D may be prepared by reacting a compound of formula C with R 4 SO 2 X wherein X is a leaving group such as Cl, Br, I, OMs, etc. in a suitable solvent (e.g. dichloromethane or DMF) advantageously, in the presence of a base (e.g. K 2 CO 3 , NaHCO 3 , Et 3 N), at a temperature ranging from about -78 degrees Celsius to the boiling point of the solvent, typically from O degrees Celsius about 100 degrees Celsius.
  • a suitable solvent e.g. dichloromethane or DMF
  • a base e.g. K 2 CO 3 , NaHCO 3 , Et 3 N
  • Compound of formula C can be prepared by removing the protecting group P in the compound of formula B.
  • the compound of formula B can be prepared by coupling the compound of formula A with a substituted or unsubstituted adamantyl-2-amine, following standard amide bond formation methods by a method known to those skilled in the art.
  • Compound formula A is an acid wherein P is a protecting functional group such as Boc or Cbz.
  • the compound of formula D can be prepared by coupling the compound of formula G with a substituted or unsubstituted adamantyl-2-amine following standard amide bond formation methods by a method known to those skilled in the art.
  • Compound of formula G may be prepared by treatment of compound of formula F, where R is an alkyl or cycloalkyl group, with a base such as NaOH, KOH, LiOH in a suitable solvent such as MeOH and water at an optimum temperature, typically ranging from room temperature to 60 degrees Celsius.
  • Compound of formula F may be prepared by reacting a compound of formula E with R 4 SO 2 X wherein X is a leaving group such as Cl, Br, I, OMs, etc.
  • a suitable solvent e.g. dichloromethane or DMF
  • a base e.g. K 2 CO 3 , NaHCO 3 , Et 3 N
  • a temperature ranging from about -78 degrees Celsius to the boiling point of the solvent, typically from O degrees Celsius about 100 degrees Celsius.
  • the compound of formula D can be prepared by treatment of the compound of formula F with a substituted or unsubstituted adamantyl-2-amine in a suitable solvent at a suitable temperature or in a suitable solvent in the presence of a Lewis acid such as AICI 3 .
  • a Lewis acid such as AICI 3 .
  • N-(tert-Butoxycarbonyl)-D-proline (43.6g, 202 mmol) was added to a slurry of 2-adamantylamine hydrochloride (38.3 g, 204 mmol), DMF (500 mL) and triethylamine (40.0 g, 395 mmol).
  • the resulting very thick suspension was stirred vigorously and cooled to 11 0 C.
  • the coupling reagent PyBOP (120.0 g, 230 mmol) in DMF (100 mL) was added while maintaining the temperature below 16 0 C and the heterogeneous reaction mixture was left in an ice-water bath overnight.
  • the reaction mixture was partitioned between water (3 L) and ethyl acetate:MTBE (1 :1.4 L). The aqueous layer was extracted with ethyl acetate:MTBE (1 :1 2x1 L). The combined organic layers were washed with brine (2x1 L) and dried over MgSO 4 , and filtered. The solvents were removed in vacuo and the product Ia was purified by chromatography (silica gel 50Og; eluted with hexanes:ethyl acetate, 3:1 ). Yield: 62.9 g.
  • Examples 2-14 Examples 2 through 14 were prepared using methods analogous to example 1 above except that the 2-chlorobenzenesulfonyl chloride was substituted with corresponding sulfonyl halide reagents. It is expected that examples 15 through 17 may also be prepared using methods analogous to example 1..
  • Examples 24 and 25 N-2-adamantyl-1- ⁇ [4-(aminocarbonyl)-2-chlorophenyl]sulfonyl ⁇ -D- prolinamide (24) and 4-( ⁇ (2R)-2-[(2-adamantylamino)carbonyl]pyrrolidin-1-yl ⁇ sulfonyl)-3- chlorobenzoic acid (25)
  • Example 26 through 29 were prepared using methods analogous to example 24 and 25 above.
  • Example 30 4-[(R)-2-(Adamantan-2-ylcarbamoyI)-pyrrolidine-1-sulfonyl]-benzoic acid methyl ester.
  • Example 31 N-2-adamantyl-1- ⁇ [4-(hydroxymethyI)phenyl]sulfonyl ⁇ -D-prolinamide.
  • lntermediate 33a ⁇ /-2-adamantyl-1-[(6-chloropyridin-3-yl)sulfonyl]-D-prolinamide
  • the sulfonamide was made using methods analogous to example 1 above, and was purified by trituration using methyl-t-butyl ether and CH 2 CI 2 .
  • piperidine analogs 34a and 34 were prepared in a manner similar to example 33 above, except that N-(tert-butoxycarbonyl)-D-proline was replaced with (3S)-1-(tert-butoxycarbonyl)piperidine-3- carboxylic acid.
  • Example 34 The title compound 34 was made by the same procedure as Example 19 and was purified by silica gel chromatography using 100% EtOAc. Examples 36 and 37:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés, des compositions pharmaceutiques contenant ces composés et des procédés destinés à traiter une pathologie liée à la modulation de l’enzyme 11-β-hsd-1.
PCT/IB2006/003287 2005-11-18 2006-11-06 Derives de sulfonyle Ceased WO2007057768A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US73815405P 2005-11-18 2005-11-18
US60/738,154 2005-11-18
US75375905P 2005-12-23 2005-12-23
US60/753,759 2005-12-23
US79920706P 2006-05-09 2006-05-09
US60/799,207 2006-05-09
US86354206P 2006-10-30 2006-10-30
US60/863,542 2006-10-30

Publications (2)

Publication Number Publication Date
WO2007057768A2 true WO2007057768A2 (fr) 2007-05-24
WO2007057768A3 WO2007057768A3 (fr) 2007-11-01

Family

ID=38049021

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/003287 Ceased WO2007057768A2 (fr) 2005-11-18 2006-11-06 Derives de sulfonyle

Country Status (1)

Country Link
WO (1) WO2007057768A2 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007125398A3 (fr) * 2006-04-27 2008-03-06 Pfizer Japan Inc Sulfonamides
WO2009021740A2 (fr) 2007-08-15 2009-02-19 Sanofis-Aventis Nouvelles tétrahydronaphtalines substituées, leurs procédés de préparation et leur utilisation comme médicaments
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
WO2011161030A1 (fr) 2010-06-21 2011-12-29 Sanofi Dérivés de méthoxyphényle à substitution hétérocyclique par un groupe oxo, leur procédé de production et leur utilisation comme modulateurs du récepteur gpr40
WO2012004270A1 (fr) 2010-07-05 2012-01-12 Sanofi Dérivés 1,3-propanedioxyde à substitution spirocyclique, procédé de préparation et utilisation comme médicament
WO2012004269A1 (fr) 2010-07-05 2012-01-12 Sanofi Dérivés d'acide ( 2 -aryloxy -acétylamino) - phényl - propionique, procédé de production et utilisation comme médicament
WO2012010413A1 (fr) 2010-07-05 2012-01-26 Sanofi Acides hydroxy-phényl-hexiniques substitués par aryloxy-alkylène, procédé de production et utilisation comme médicament
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120053A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012134233A2 (fr) 2011-03-31 2012-10-04 한국화학연구원 Dérivé de sulfamide possédant un groupe adamantyle et un sel pharmaceutiquement acceptable de celui-ci
WO2013020440A1 (fr) * 2011-08-09 2013-02-14 上海医药集团股份有限公司 Dérivés d'amide et son procédé de préparation, composition pharmaceutique et son utilisation
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2013019091A3 (fr) * 2011-08-04 2013-04-25 Hyundai Pharm Co., Ltd. Composé d'inhibition de la 11β-hydroxystéroïde déshydrogénase de type 1, et composition pharmaceutique le comprenant
CN103168028A (zh) * 2010-09-03 2013-06-19 大日本住友制药株式会社 环酰胺衍生物
US8524894B2 (en) 2009-06-04 2013-09-03 Laboratorios Salvat, S.A. Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1
WO2017102587A1 (fr) * 2015-12-14 2017-06-22 Dsm Ip Assets B.V. Dérivés (r)-n-(adamantyl-2-yl)pyrrolidine-2-carboxamide destinés à une utilisation cosmétique
EP3235813A1 (fr) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Dérivés aza-tétra-cycliques
WO2017222914A1 (fr) 2016-06-21 2017-12-28 Inception 4, Inc. Dérivés de prolinamide carbocycliques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056744A1 (fr) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides utilises comme inhibiteurs de la hydroxysteroide deshydrogenase
US20050245745A1 (en) * 2004-04-29 2005-11-03 Link James T Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007125398A3 (fr) * 2006-04-27 2008-03-06 Pfizer Japan Inc Sulfonamides
WO2009021740A2 (fr) 2007-08-15 2009-02-19 Sanofis-Aventis Nouvelles tétrahydronaphtalines substituées, leurs procédés de préparation et leur utilisation comme médicaments
US8524894B2 (en) 2009-06-04 2013-09-03 Laboratorios Salvat, S.A. Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1
US8822452B2 (en) 2009-06-04 2014-09-02 Laboratorios Salvat, S.A. Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
WO2011161030A1 (fr) 2010-06-21 2011-12-29 Sanofi Dérivés de méthoxyphényle à substitution hétérocyclique par un groupe oxo, leur procédé de production et leur utilisation comme modulateurs du récepteur gpr40
WO2012004270A1 (fr) 2010-07-05 2012-01-12 Sanofi Dérivés 1,3-propanedioxyde à substitution spirocyclique, procédé de préparation et utilisation comme médicament
WO2012004269A1 (fr) 2010-07-05 2012-01-12 Sanofi Dérivés d'acide ( 2 -aryloxy -acétylamino) - phényl - propionique, procédé de production et utilisation comme médicament
WO2012010413A1 (fr) 2010-07-05 2012-01-26 Sanofi Acides hydroxy-phényl-hexiniques substitués par aryloxy-alkylène, procédé de production et utilisation comme médicament
US8895552B2 (en) 2010-09-03 2014-11-25 Sumitomo Dainippon Pharma Co., Ltd. Cyclic amide derivative
CN103168028A (zh) * 2010-09-03 2013-06-19 大日本住友制药株式会社 环酰胺衍生物
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120053A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
KR101332805B1 (ko) * 2011-03-31 2013-11-27 한국화학연구원 아다만틸기를 갖는 설파마이드 유도체 및 이의 약제학적으로 허용 가능한 염
JP2014517812A (ja) * 2011-03-31 2014-07-24 コリア リサーチ インスティテュート オブ ケミカル テクノロジー アダマンチル基を有するスルファミド誘導体及びこれの薬剤学的に許容可能な塩
CN104080766B (zh) * 2011-03-31 2017-02-15 韩国化学研究院 含有金刚烷基的磺酰胺衍生物及药剂学上可接受的其盐
US9073906B2 (en) 2011-03-31 2015-07-07 Korea Research Institute Of Chemical Technology Sulfamide derivative having an adamantyl group and its pharmaceutically acceptable salt
EP2740723A4 (fr) * 2011-03-31 2015-01-07 Korea Res Inst Chem Tech Dérivé de sulfamide possédant un groupe adamantyle et un sel pharmaceutiquement acceptable de celui-ci
WO2012134233A2 (fr) 2011-03-31 2012-10-04 한국화학연구원 Dérivé de sulfamide possédant un groupe adamantyle et un sel pharmaceutiquement acceptable de celui-ci
CN104080766A (zh) * 2011-03-31 2014-10-01 韩国化学研究院 含有金刚烷基的磺酰胺衍生物及药剂学上可接受的其盐
WO2012134233A3 (fr) * 2011-03-31 2013-01-10 한국화학연구원 Dérivé de sulfamide possédant un groupe adamantyle et un sel pharmaceutiquement acceptable de celui-ci
US9073830B2 (en) 2011-08-04 2015-07-07 Hyundai Pharm Co., Ltd. Compound for inhibiting 11β-hydroxy steroid dehydrogenase 1, and a pharmaceutical composition comprising the same
KR101409847B1 (ko) * 2011-08-04 2014-06-27 현대약품 주식회사 인간 11-베타-히드록시스테로이드 탈수소효소 타입 1을 억제하는 화합물 및 이를 포함하는 약학조성물
CN103857655A (zh) * 2011-08-04 2014-06-11 现代药品株式会社 用于抑制11β-羟基类固醇脱氢酶1的化合物及包含该化合物的药物组合物
CN103857655B (zh) * 2011-08-04 2016-03-30 现代药品株式会社 用于抑制11β-羟基类固醇脱氢酶1的化合物及包含该化合物的药物组合物
WO2013019091A3 (fr) * 2011-08-04 2013-04-25 Hyundai Pharm Co., Ltd. Composé d'inhibition de la 11β-hydroxystéroïde déshydrogénase de type 1, et composition pharmaceutique le comprenant
WO2013020440A1 (fr) * 2011-08-09 2013-02-14 上海医药集团股份有限公司 Dérivés d'amide et son procédé de préparation, composition pharmaceutique et son utilisation
CN102952059A (zh) * 2011-08-09 2013-03-06 上海医药集团股份有限公司 酰胺衍生物、其制备方法、药物组合物和应用
CN102952059B (zh) * 2011-08-09 2015-03-18 上海医药集团股份有限公司 酰胺衍生物、其制备方法、药物组合物和应用
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
JP2018536664A (ja) * 2015-12-14 2018-12-13 ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． 化粧品使用のための（ｒ）−ｎ−（アダマンチル−２−イル）ピロリジン−２−カルボキサミド誘導体
CN108368041A (zh) * 2015-12-14 2018-08-03 帝斯曼知识产权资产管理有限公司 用于美容用途的(r)-n-(金刚烷基-2-基)吡咯烷-2-甲酰胺衍生物
KR20180095852A (ko) * 2015-12-14 2018-08-28 디에스엠 아이피 어셋츠 비.브이. 화장품 용도를 위한 (r)-n-(아다만틸-2-일)피롤리딘-2-카복스아미드 유도체
WO2017102587A1 (fr) * 2015-12-14 2017-06-22 Dsm Ip Assets B.V. Dérivés (r)-n-(adamantyl-2-yl)pyrrolidine-2-carboxamide destinés à une utilisation cosmétique
US10470991B2 (en) 2015-12-14 2019-11-12 Dsm Ip Assets B.V. (R)-N-(adamantyl-2-yl)pyrrolidine-2-carboxamide derivatives for cosmetic use
CN108368041B (zh) * 2015-12-14 2021-09-07 帝斯曼知识产权资产管理有限公司 用于美容用途的(r)-n-(金刚烷基-2-基)吡咯烷-2-甲酰胺衍生物
KR102786072B1 (ko) 2015-12-14 2025-03-26 디에스엠 아이피 어셋츠 비.브이. 화장품 용도를 위한 (r)-n-(아다만틸-2-일)피롤리딘-2-카복스아미드 유도체
EP3235813A1 (fr) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Dérivés aza-tétra-cycliques
WO2017182464A1 (fr) 2016-04-19 2017-10-26 Cidqo 2012, S.L. Nouveaux dérivés d'aza-tétracyclo
WO2017222914A1 (fr) 2016-06-21 2017-12-28 Inception 4, Inc. Dérivés de prolinamide carbocycliques
EP3472151A4 (fr) * 2016-06-21 2020-03-04 Orion Ophthalmology LLC Dérivés de prolinamide carbocycliques
US11866422B2 (en) 2016-06-21 2024-01-09 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives

Also Published As

Publication number Publication date
WO2007057768A3 (fr) 2007-11-01

Similar Documents

Publication Publication Date Title
WO2007057768A2 (fr) Derives de sulfonyle
EP1745019A1 (fr) Nouveaux composes de derives de proline et de morpholine
US20070027118A1 (en) Novel compounds of amino sulfonyl derivatives
US5574044A (en) Muscarine antagonists
CA2585735A1 (fr) Nouveaux composes d'adamantyl amides substitues ou non
EP1696915A1 (fr) Derives de benzenesulfonylamino-pyridin-2yl et composes apparentes en tant qu'inhibiteurs de la 11-beta-hydeoxysteroide deshydrogenase type 1 (11-beta-hsd-1) pour le traitement du diabete et de l'obesite
WO2006134481A1 (fr) Inhibiteurs de la 11-beta hydroxysteroide deshydrogenase de type 1
US8859608B2 (en) Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction
TW202334129A (zh) 作為ｇｌｐ—１ｒ促效劑的化合物
CN115397412A (zh) Mas相关g蛋白受体x4的调节剂及相关产物和方法
PT2178858E (pt) Novos compostos heterocíclicos como antagonistas de mglu5
CN101602741A (zh) 作为γ-分泌酶抑制剂的取代的N-芳基磺酰基杂环胺
KR20220079593A (ko) 키나제 억제제로서의 인다졸 카르복스아미드
KR20180002729A (ko) 히스톤 탈아세틸효소 억제제 및 그것의 조성물 및 사용 방법
US5834482A (en) Heterocyclic chemistry
WO2001025199A1 (fr) Composes d'uree, procede de production et d'utilisation de ces derniers
KR20070046879A (ko) 5-ｈｔ7 수용체 안타고니스트
IE912851A1 (en) 3-(1,2-Benzisoxazol-3-yl)-4-pyridinamines and derivatives
SK286977B6 (sk) Morfolínové deriváty, spôsob ich prípravy a farmaceutické prostriedky obsahujúce tieto zlúčeniny a ich použitie
WO2019149205A1 (fr) Dérivé de benzohétéroaryle et son procédé de préparation et son application médicale
WO2002022574A1 (fr) Compose tricyclique heterocyclique, son procede de fabrication et son utilisation
KR20070046878A (ko) 5-ｈｔ7 수용체 안타고니스트
TW201038562A (en) Azetidines as histamine H3 receptor antagonists
TWI901639B (zh) 雜環glp-1促效劑
ZA200604887B (en) Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteriod dehydrogenase type 1(11-beta-HSD-1) for the treatment of diabetes and obesity

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06820933

Country of ref document: EP

Kind code of ref document: A2